登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600998 证券简称：九州通 公告编号：临2025-053 2025年7月4日，公司收到基金管理人通知，该产业基金已在中国证券投资基金业协会完成备案手续，并 取得了《私募投资基金备案证明》，备案信息主要内容如下： 一、基金名称：北京智汇九州创业投资合伙企业（有限合伙） 关于全资孙公司投资设立的产业基金完成备案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 为进一步促进旗下产业孵化器发展，满足行业对孵化器的"孵化器+产业基金"模式的要求，加大九州通 医药集团股份有限公司（以下简称"公司"）在医药大健康、科技领域的战略布局，公司全资孙公司北京 九州通科技孵化器有限公司和北京楚昌私募基金管理有限公司、谢家芳共同投资设立北京智汇九州创业 投资合伙企业（有限合伙）（以下简称"产业基金"），投资于药品、医疗器械、医美、抗衰等领域。具 体内容详见公司于2025年5月17日在《中国证券报》《证券时报》《上海证券报》《证券日报》以及上 海证券交易所网站（www.sse.com ...

Overview - The article discusses the establishment of an industrial fund by a wholly-owned subsidiary of Jiuzhoutong Pharmaceutical Group in collaboration with professional investment institutions, which constitutes a related party transaction [1][2]. Fund Establishment and Related Transactions - The industrial fund, named Beijing Zhihui Jiuzhou Venture Capital Partnership, has a total subscribed capital of 25 million RMB, with Jiuzhoutong Incubator contributing 22.99 million RMB, representing 91.96% of the total [1][3]. - The investment aims to enhance the company's strategic layout in the pharmaceutical and technology sectors, focusing on areas such as pharmaceuticals, medical devices, and anti-aging [1][8]. Related Party Transaction Details - The investment constitutes a related party transaction as Chuchang Private Fund is a subsidiary of the company's controlling shareholder, Chuchang Investment Group, but does not qualify as a major asset restructuring [2]. - In the past 12 months, the company has engaged in related party transactions with Chuchang Private Fund totaling 336.54 million RMB [2]. Investment Partners - The general partner of the fund is Beijing Chuchang Private Fund Management Co., Ltd., while other limited partners include Jiuzhoutong Incubator and Ms. Xie Jiafang [3][4]. Fund Operations and Management - The fund will primarily focus on early-stage incubation projects in the pharmaceutical and technology sectors, with a planned investment period of 5 years and an optional extension of 2 years [4][5]. Financial Impact - The investment will be funded by the company's own resources and is not expected to adversely affect the company's operational activities or financial performance [8]. - The establishment of the fund is anticipated to enhance the company's core competitiveness in products, technology, and services by leveraging the advantages of the incubator and the capital provided by the fund [8]. Regulatory Compliance - The sponsor, CITIC Securities, has confirmed that the transaction complies with relevant regulations and does not require board or shareholder approval [8].